Black Diamond Therapeutics, Inc. — Director's Dealing 2021

Mar 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-03-18

Reporting Person: Behbahani Ali (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-18	Common Stock	A	547	$24.01	Acquired	547	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3448757	Indirect

Footnotes

F1: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2: The price of reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 18, 2021.

F3: The Reporting Person is a manager of NEA 16 GP, LLC ("NEA 16 GP"), which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest.